Patent 7511154 was granted and assigned to Basilea Pharmaceutica on March, 2009 by the United States Patent and Trademark Office.
A process for producing the compound (1′benzyl-2-oxo-[1,3′]-(R)-bipyrrolidinyl-3-(R,S)-yl)-triphenyl-phosphonium bromide which is an intermediate for antibacterial vinylpyrrolidinone-cephalosporin derivatives.